Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study - 23/12/25
, Yu Yao, ProfMD b, †, Jin-Ji Yang, ProfMD a, Lin Wu, ProfPhD c, Wei Zhang, ProfPhD d, Ying Wang, ProfMD e, Hai-Peng Xu, ProfPhD f, Yong Song, ProfMD g, Yan Zhang, ProfMD h, i, Jun Zhao, ProfMD j, Jing-Hua Chen, ProfPhD k, Zhe-Hai Wang, ProfMD l, Qi-Ming Wang, ProfPhD m, n, Jie Hu, ProfMD o, Xing-Ya Li, ProfMD p, Yun Fan, ProfMD q, Yuan Chen, ProfMD r, Jian Fang, ProfMD s, Di Han, BP t, Wei-Zhe Xue, PhD u, Si-yang Maggie Liu, ProfPhD a, Qing Zhou, ProfPhD a, Pei-Long Zhang, PhD v, He-Peng Shi, PhD vSummary |
Background |
MET amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and safety of vebreltinib, a potent and highly selective MET inhibitor, in patients with MET amplification-driven NSCLC.
Methods |
KUNPENG was a multicentre, multi-cohort, single-arm, phase 2 trial conducted across 17 hospitals in China, in patients with locally advanced or metastatic NSCLC with MET dysregulation. Patients were eligible if they were MET inhibitor-naive, aged 18 years or older with MET amplification-driven NSCLC (gene copy number of six or higher), and progressed after previous standard chemotherapy or were ineligible for chemotherapy (cohort 2) or refused chemotherapy (cohort 3). Patients received 200 mg vebreltinib orally twice daily until disease progression or intolerable toxicity. The primary endpoint was the objective response rate, assessed by a masked independent review committee in the full analysis set. The study was amended to merge cohorts 2 and 3 due to slow accrual and was closed to enrolment on Nov 14, 2023. This trial is registered with ClinicalTrials.gov ( NCT04258033 ).
Findings |
Between Jan 17, 2020, and Nov 14, 2023, 145 patients were enrolled; of these, 86 patients (30 chemotherapy-treated and 56 untreated) from cohorts 2 and 3 were included in the current analysis. The median age was 65 years (range 48–82; IQR 59–71), 77 (90%) patients were male, and nine (10%) were female. All patients were Chinese. 42 patients had partial response, resulting in an objective response rate of 48·8% (42 of 86; 95% CI 38·3–59·4) per masked independent review committee. The median follow-up was 18·6 months (IQR 15·7–37·3). The incidence of grade 3 or worse treatment-related adverse events was 31% (27 of 86), predominantly abnormal liver function terms reported by the investigators (eight [9%]). Serious adverse events related to treatment were reported by 16 (19%) patients. 11 treatment-emergent adverse events leading to death occurred, of which one patient died of abnormal liver function, which was possibly related to vebreltinib treatment.
Interpretation |
Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.
Funding |
Beijing Pearl Biotechnology and Avistone Biotechnology.
Le texte complet de cet article est disponible en PDF.Plan
Vol 27 - N° 1
P. 36-44 - janvier 2026 Retour au numéro
Article précédent
- Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
- Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L A Koppe, Marlies E Nowee, Henrike Westerveld, Maria A A De Jong, Filip Frühauf, Jeltsje S Cnossen, Jan Willem M Mens, Jannet C Beukema, Cyrus Chargari, Charles Gillham, Ina M Jurgenliemk-Schulz, Katrien Vandecasteele, Moritz Hamann, Mandy Kiderlen, Annette Staebler, Hans W Nijman, Bastiaan G Wortman, Elefteria Asteinidou, Stephanie M de Boer, Wilbert B van den Hout, Karen W Verhoeven-Adema, Remi A Nout, Hein Putter, Tjalling Bosse, Carien L Creutzberg
- Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
- Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Jean-François Baurain, Warren P Mason, Helen Wheeler, Emeline Tabouret, Sanjeev Gill, Matthew Griffin, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap C Reijneveld, Roelien H Enting, Sébastien Tran, Thierry Lesimple, Martin Kocher, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Youri Hoogstrate, Sarah Nuyens, Vassilis Golfinopoulos, C Mircea S Tesileanu, Thierry Gorlia, Pim French, Brigitta G Baumert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?